Lymphoma: Clinical Trials Open for Enrollment
-
Eligibility
- Subject is between three years and 31 years of age
- In first or second relapse or primary induction failure CD20 positive B-cell leukemia/lymphoma
Enrollment Status: Enrolling
Study Information
ClinicalTrials.gov | NCT02393157
Principal Investigator
Mitchell Cairo, MD
Contact for Study Screening
-
Eligibility
- Subject is between one year and 31 years of age
- Patients must weigh at least 10 kilograms at the time of the study enrollment
- Newly diagnosed patients with histologically proven mature T- and NK- cell neoplasms
Enrollment Status: Enrolling
Study Information
ClinicalTrials.gov | NCT03719105
Principal Investigator
Aliza Gardenswartz, MD
Contact for Study Screening
-
Eligibility
- Subject is between one year and 30 years of age
- Disease: B-ALL
Enrollment Status: Enrolling
Study Information
ClinicalTrials.gov | NCT03914625
Principal Investigator
Jessica Hochberg, MD
Contact for Study Screening
-
Eligibility
- Subject is between one year and 31 years of age
- B-cell Lymphoblastic Leukemia
- B-cell Lymphoblastic Lymphoma
Enrollment Status: Enrolling
Study Information
ClinicalTrials.gov | NCT03914625
Principal Investigator
Jessica Hochberg, MD
Contact for Study Screening
-
Enrollment Status: Enrolling
Principal Investigator
Aliza Gardenswartz, MD
Contact for Study Screening
-
Enrollment Status: Enrolling
Study Information
ClinicalTrials.gov | NCT05253495
Principal Investigator
Jessica Hochberg, MD
Contact for Study Screening
-
Eligibility
- Subject is at least two years of age
- Primary mediastinal B-cell lymphoma (PMBCL)
Enrollment Status: Enrolling
Study Information
ClinicalTrials.gov | NCT04759586
Principal Investigator
Jessica Hochberg, MD
Contact for Study Screening
-
Eligibility
- Male or female at least 15 years of age
- Newly Diagnosed B-ALL, T-ALL, Lymphoblastic Lymphoma (LLy), or Mixed-Phenotype Acute Leukemia/Lymphoma (MPAL)
Enrollment Status: Enrolling
Principal Investigator
Jessica Hochberg, MD
Contact for Study Screening
-
Eligibility
- Male or Female must be ≥ 3 years and ≤ 39 years of age at the time of enrollment
- Newly diagnosed patients with histologically or cytologically proven newly diagnosed cHL according to WHO Classification who meet the following criteria are eligible:
COHORT 1:- Classical Hodgkin lymphoma (ICD-O 9650/3, 9663/3, 9651/3, 9652/3, 9653/3)
- COHORT Ia: stage I-IIA with bulky ± E, I-IIB no bulky ± E, IIIA ± E (INTERMEDIATE RISK)
- COHORT Ib: stage IIB with bulky ± E, IIIA with bulky ± E, IIIB, IV (HIGH RISK)
- Adequate organ function
- Exclusion Criteria
- Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)
- Female patients who are pregnant. Pregnancy tests must be obtained in girls who are post menarchal
- Lactating females unless they have agreed not to breastfeed their infants
- Any patient with uncontrolled infection prior to study entry
- Any patient known to have primary or acquired immunodeficiency and/or prior solid organ transplant
- Patients who have received any prior lymphoma directed therapy.
EXCEPTION: emergent steroid therapy will be eligible only if given ≤72 h prior to enrollment; mediastinal radiation therapy may be given prior to or concurrently (<1000 cGy) for superior vena cava (SVC) syndrome
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT05253495
Principal Investigator
Jessica Hochberg, MD
Contact for Study Screening